Income Statement Cizzle Biotechnology Holdings Plc
Equities
PSL
GB00BNG2VN02
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.550 GBX | +10.71% |
|
0.00% | - |
| 05/11 | Cizzle Biotechnology Raises Funds via Convertible Loan Note Issue | MT |
| 05/11 | Cizzle Biotechnology announces LOI with leading UK clinical diagnostic group | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | - | |||||
Total Revenues | - | - | - | - | - | |||||
Cost of Goods Sold, Total | - | - | - | - | - | |||||
Gross Profit | - | - | - | - | - | |||||
Selling General & Admin Expenses, Total | 14T | 6L | 10L | 10L | 9L | |||||
R&D Expenses | - | 2L | - | - | - | |||||
Other Operating Expenses | - | - | - | - | - | |||||
Other Operating Expenses, Total | 14T | 8L | 10L | 10L | 9L | |||||
Operating Income | -14T | -8L | -10L | -10L | -9L | |||||
Interest And Investment Income | - | - | - | - | - | |||||
Net Interest Expenses | - | - | - | - | - | |||||
Other Non Operating Income (Expenses) | - | -53T | - | - | 80T | |||||
EBT, Excl. Unusual Items | -14T | -9L | -10L | -10L | -8L | |||||
Merger & Related Restructuring Charges | - | -31.07L | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | - | - | -7L | -13.91L | |||||
Gain (Loss) On Sale Of Assets | - | - | - | 44T | - | |||||
Other Unusual Items | - | - | - | -1L | - | |||||
EBT, Incl. Unusual Items | -14T | -39.58L | -10L | -17.63L | -21.87L | |||||
Income Tax Expense | - | -37T | -51T | -46T | -21T | |||||
Earnings From Continuing Operations | -14T | -39.21L | -9L | -17.17L | -21.66L | |||||
Net Income to Company | -14T | -39.21L | -9L | -17.17L | -21.66L | |||||
Net Income - (IS) | -14T | -39.21L | -9L | -17.17L | -21.66L | |||||
Net Income to Common Incl Extra Items | -14T | -39.21L | -9L | -17.17L | -21.66L | |||||
Net Income to Common Excl. Extra Items | -14T | -39.21L | -9L | -17.17L | -21.66L | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.03 | -0.02 | -0 | -0 | -0.01 | |||||
Basic EPS - Continuing Operations | -0.03 | -0.02 | -0 | -0 | -0.01 | |||||
Basic Weighted Average Shares Outstanding | 5L | 16Cr | 29Cr | 36Cr | 39Cr | |||||
Net EPS - Diluted | -0.03 | -0.02 | -0 | -0 | -0.01 | |||||
Diluted EPS - Continuing Operations | -0.03 | -0.02 | -0 | -0 | -0.01 | |||||
Diluted Weighted Average Shares Outstanding | 5L | 16Cr | 29Cr | 36Cr | 39Cr | |||||
Normalized Basic EPS | -0.02 | -0 | -0 | -0 | -0 | |||||
Normalized Diluted EPS | -0.02 | -0 | -0 | -0 | -0 | |||||
Supplemental Items | ||||||||||
EBITDA | - | - | - | - | - | |||||
EBITA | -14T | -8L | -10L | -10L | -9L | |||||
EBIT | -14T | -8L | -10L | -10L | -9L | |||||
Effective Tax Rate - (Ratio) | - | 0.93 | 5.3 | 2.61 | 0.96 | |||||
Total Current Taxes | - | - | - | - | - | |||||
Normalized Net Income | -8.75T | -5L | -6L | -6L | -5L | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 14T | 5L | 10L | 10L | 9L | |||||
Research And Development Expense From Footnotes | - | 2L | 3L | 2L | 2L | |||||
Stock-Based Comp., G&A Exp. (Total) | - | 31.4L | 1L | 3L | 2L | |||||
Total Stock-Based Compensation | - | 31.4L | 1L | 3L | 2L |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















